The Department of Health and Human Services (HHS) has decided to temporarily allow compounding pharmacies to produce six specific peptides, which are not yet approved for general use, as it works on a formal regulatory change. This move is seen as a step towards increasing access to these substances while ensuring safety protocols are in place.
In an announcement made on Wednesday, HHS stated that it would exercise “enforcement discretion,” effectively halting legal action against pharmacies making these peptides. This means that consumers can expect to see these substances available sooner than previously anticipated, despite them not being listed on the Food and Drug Administration’s (FDA) approved ingredients list.
The six peptides in question include BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500, which have been marketed online for various health benefits, ranging from accelerated healing to anti-aging effects. However, the FDA has not approved any of these peptides, citing a lack of sufficient data to validate their safety and efficacy.
While compounding pharmacies are now permitted to produce these peptides, they are required to certify the identity and purity of the compounds and report any side effects—requirements that were not previously enforced. The decision comes in response to a growing “gray market” for peptides, where unregulated products are sold under the label of “for research use only,” circumventing FDA oversight.
Health Secretary Robert F. Kennedy Jr. has advocated for this change, suggesting that allowing these peptides to be compounded will help divert consumers from potentially hazardous products in the gray market to more reliable options. “Under President Trump’s leadership, HHS is working to put prevention and patient safety at the center of health care,” stated Emily Hilliard, an HHS spokesperson.
However, not everyone is in favor of this development. Dr. Peter Lurie, a former FDA official, has expressed concern that the FDA is essentially ignoring the dangers of promoting drugs that have not been proven effective. Shabbir Safdar, the executive director of the Partnership for Safe Medicines, voiced similar worries, stating that this could expose Americans to untested substances.
As the HHS begins to facilitate access to these peptides, the long-term implications on public health and safety remain to be seen, especially as the agency navigates the regulatory process to potentially include these substances in the FDA’s official list.
Photo credit: Heather Diehl
